nach oben

Diabetologia

Erschienen in:

01.09.2012 | Review

Adiponectin: mechanistic insights and clinical implications

verfasst von: A. T. Turer, P. E. Scherer

Erschienen in: Diabetologia | Ausgabe 9/2012

Einloggen, um Zugang zu erhalten

Abstract

Adiponectin is an adipocyte-derived secretory protein that has been very widely studied over the past 15 years. A multitude of different functions have been attributed to this adipokine. It has been characterised in vitro at the level of tissue culture systems and in vivo through genetic manipulation of rodent models. It is also widely accepted as a biomarker in clinical studies. Originating in adipose tissue, generally positive metabolic effects have been attributed to adiponectin. In this review, we briefly discuss the key characteristics of this interesting but very complex molecule, highlight recent results in the context of its mechanism of action and summarise some of the key epidemiological data that helped establish adiponectin as a robust biomarker for insulin sensitivity, cardiovascular disease and many additional disease phenomena.

Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF (1995) A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 270:26746–26749PubMedCrossRef

Hu E, Liang P, Spiegelman BM (1996) AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 271:10697–10703PubMedCrossRef

Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K (1996) cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun 221:286–289PubMedCrossRef

Nakano Y, Tobe T, Choi-Miura NH, Mazda T, Tomita M (1996) Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. J Biochem 120:803–812PubMedCrossRef

Arita Y, Kihara S, Ouchi N et al (1999) Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257:79–83PubMedCrossRef

Schraw T, Wang ZV, Halberg N, Hawkins M, Scherer PE (2008) Plasma adiponectin complexes have distinct biochemical characteristics. Endocrinology 149:2270–2282PubMedCrossRef

Hara K, Horikoshi M, Yamauchi T et al (2006) Measurement of the high-molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome. Diabetes Care 29:1357–1362PubMedCrossRef

Zhu N, Pankow JS, Ballantyne CM et al (2010) High-molecular-weight adiponectin and the risk of type 2 diabetes in the ARIC Study. J Clin Endocrinol Metab 92:5097–5104CrossRef

Davis KE, Scherer PE (2008) Adiponectin: no longer the lone soul in the fight against insulin resistance? Biochem J 416:e7–e9PubMedCrossRef

10.

Yamauchi T, Kamon J, Ito Y et al (2003) Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423:762–769PubMedCrossRef

11.

Yamauchi T, Nio Y, Maki T et al (2007) Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med 13:332–339PubMedCrossRef

12.

Hug C, Wang J, Ahmad NS, Bogan JS, Tsao TS, Lodish HF (2004) T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin. Proc Natl Acad Sci USA 101:10308–10313PubMedCrossRef

13.

Denzel MS, Scimia MC, Zumstein PM, Walsh K, Ruiz-Lozano P, Ranscht B (2010) T-cadherin is critical for adiponectin-mediated cardioprotection in mice. J Clin Invest 120:4342–4352PubMedCrossRef

14.

Awazawa M, Ueki K, Inabe K et al (2011) Adiponectin enhances insulin sensitivity by increasing hepatic IRS-2 expression via a macrophage-derived IL-6-dependent pathway. Cell Metab 13:401–412PubMedCrossRef

15.

Mao X, Kikani CK, Riojas RA et al (2006) APPL1 binds to adiponectin receptors and mediates adiponectin signalling and function. Nat Cell Biol 8:516–523PubMedCrossRef

16.

Pischon T, Hotamisligil GS, Rimm EB (2003) Adiponectin: stability in plasma over 36 hours and within-person variation over 1 year. Clin Chem 49:650–652PubMedCrossRef

17.

Halberg N, Schraw TD, Wang ZV et al (2009) Systemic fate of the adipocyte-derived factor adiponectin. Diabetes 58:1961–1970PubMedCrossRef

18.

Turer AT, Khera A, Ayers CR et al (2011) Adipose tissue mass and location affect circulating adiponectin levels. Diabetologia 54:2515–2524PubMedCrossRef

19.

Li S, Shin HJ, Ding EL, van Dam RM (2009) Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 302:179–188PubMedCrossRef

20.

Huypens P, Moens K, Heimberg H, Ling Z, Pipeleers D, van de Casteele M (2005) Adiponectin-mediated stimulation of AMP-activated protein kinase (AMPK) in pancreatic beta cells. Life Sci 77:1273–1282PubMedCrossRef

21.

Kharroubi I, Rasschaert J, Eizirik DL, Cnop M (2003) Expression of adiponectin receptors in pancreatic beta cells. Biochem Biophys Res Commun 312:1118–1122PubMedCrossRef

22.

Staiger K, Stefan N, Staiger H et al (2005) Adiponectin is functionally active in human islets but does not affect insulin secretory function or beta-cell lipoapoptosis. J Clin Endocrinol Metab 90:6707–6713PubMedCrossRef

23.

Wijesekara N, Krishnamurthy M, Bhattacharjee A, Suhail A, Sweeney G, Wheeler MB (2010) Adiponectin-induced ERK and Akt phosphorylation protects against pancreatic beta cell apoptosis and increases insulin gene expression and secretion. J Biol Chem 285:33623–33631PubMedCrossRef

24.

Winzell MS, Nogueiras R, Dieguez C, Ahrén B (2004) Dual action of adiponectin on insulin secretion in insulin-resistant mice. Biochem Biophys Res Commun 321:154–160PubMedCrossRef

25.

Holland WL, Miller RA, Wang ZV et al (2011) Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin. Nat Med 17:55–63PubMedCrossRef

26.

Brown JE, Conner AC, Digby JE et al (2010) Regulation of beta-cell viability and gene expression by distinct agonist fragments of adiponectin. Peptides 31:944–949PubMedCrossRef

27.

Rakatzi I, Mueller H, Ritzeler O, Tennagels N, Eckel J (2004) Adiponectin counteracts cytokine- and fatty acid-induced apoptosis in the pancreatic beta-cell line INS-1. Diabetologia 47:249–258PubMedCrossRef

28.

Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB (2004) Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 291:1730–1737PubMedCrossRef

29.

Shibata R, Sato K, Pimentel DR et al (2005) Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. Nat Med 11:1096–1103PubMedCrossRef

30.

Cavusoglu E, Ruwende C, Chopra V et al (2006) Adiponectin is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction in patients presenting with chest pain. Eur Heart J 27:2300–2309PubMedCrossRef

31.

Sharma K (2009) The link between obesity and albuminuria: adiponectin and podocyte dysfunction. Kidney Int 76:145–148PubMedCrossRef

32.

Zoccali C, Mallamaci F (2011) Adiponectin and leptin in chronic kidney disease: causal factors or mere risk markers? J Ren Nutr 21:87–91PubMedCrossRef

33.

Ohashi K, Iwatani H, Kihara S et al (2007) Exacerbation of albuminuria and renal fibrosis in subtotal renal ablation model of adiponectin-knockout mice. Arterioscler Thromb Vasc Biol 27:1910–1917PubMedCrossRef

34.

Sharma K, Ramachandrarao S, Qiu G et al (2008) Adiponectin regulates albuminuria and podocyte function in mice. J Clin Invest 118:1645–1656PubMed

35.

Lo MM, Salisbury S, Scherer PE, Furth SL, Warady BA, Mitsnefes MM (2011) Serum adiponectin complexes and cardiovascular risk in children with chronic kidney disease. Pediatr Nephrol 26:2009–2017PubMedCrossRef

36.

von Eynatten M, Liu D, Hock C et al (2009) Urinary adiponectin excretion: a novel marker for vascular damage in type 2 diabetes. Diabetes 58:2093–2099CrossRef

37.

Chen MB, McAinch AJ, Macaulay SL et al (2005) Impaired activation of AMP-kinase and fatty acid oxidation by globular adiponectin in cultured human skeletal muscle of obese type 2 diabetics. J Clin Endocrinol Metab 90:3665–3672PubMedCrossRef

38.

Debard C, Laville M, Berbe V et al (2004) Expression of key genes of fatty acid oxidation, including adiponectin receptors, in skeletal muscle of type 2 diabetic patients. Diabetologia 47:917–925PubMedCrossRef

39.

Tomas E, Tsao TS, Saha AK et al (2002) Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation. Proc Natl Acad Sci USA 99:16309–16313PubMedCrossRef

40.

Yamauchi T, Kamon J, Minokoshi Y et al (2002) Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8:1288–1295PubMedCrossRef

41.

Fruebis J, Tsao TS, Javorschi S et al (2001) Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA 98:2005–2010PubMed

42.

Civitarese AE, Ukropcova B, Carling S et al (2006) Role of adiponectin in human skeletal muscle bioenergetics. Cell Metab 4:75–87PubMedCrossRef

43.

Yamauchi T, Kamon J, Waki H et al (2003) Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem 278:2461–2468PubMedCrossRef

44.

Ceddia RB, Somwar R, Maida A, Fang X, Bikopoulos G, Sweeney G (2005) Globular adiponectin increases GLUT4 translocation and glucose uptake but reduces glycogen synthesis in rat skeletal muscle cells. Diabetologia 48:132–139PubMedCrossRef

45.

Iwabu M, Yamauchi T, Okada-Iwabu M et al (2010) Adiponectin and AdipoR1 regulate PGC-1α and mitochondria by Ca²⁺ and AMPK/SIRT1. Nature 464:1313–1319PubMedCrossRef

46.

Tsuchida A, Yamauchi T, Ito Y et al (2004) Insulin/Foxo1 pathway regulates expression levels of adiponectin receptors and adiponectin sensitivity. J Biol Chem 279:30817–30822PubMedCrossRef

47.

Nawrocki AR, Rajala MW, Tomas E et al (2006) Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor γ agonists. J Biol Chem 281:2654–2660PubMedCrossRef

48.

Combs TP, Pajvani UB, Berg AH et al (2004) A transgenic mouse with a deletion in the collagenous domain of adiponectin displays elevated circulating adiponectin and improved insulin sensitivity. Endocrinology 145:367–383PubMedCrossRef

49.

Combs TP, Berg AH, Obici S, Scherer PE, Rossetti L (2001) Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. J Clin Invest 108:1875–1881PubMed

50.

Berg AH, Combs TP, Du X, Brownlee M, Scherer PE (2001) The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 7:947–953PubMedCrossRef

51.

Miller RA, Chu Q, Le Lay J et al (2011) Adiponectin suppresses gluconeogenic gene expression in mouse hepatocytes independent of LKB1-AMPK signaling. J Clin Invest 121:2518–2528PubMedCrossRef

52.

Kim JY, van de Wall E, Laplante M et al (2007) Obesity-associated improvements in metabolic profile through expansion of adipose tissue. J Clin Invest 117:2621–2637PubMedCrossRef

53.

Asterholm IW, Scherer PE (2010) Enhanced metabolic flexibility associated with elevated adiponectin levels. Am J Pathol 176:1364–1376PubMedCrossRef

54.

Polyzos SA, Toulis KA, Goulis DG, Zavos C, Kountouras J (2011) Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis. Metabolism 60:313–326PubMedCrossRef

55.

Shetty S, Ramos-Roman MA, Cho YR et al (2012) Enhanced fatty acid flux triggered by adiponectin overexpression. Endocrinology 153:113–122PubMedCrossRef

56.

Rasmussen MS, Lihn AS, Pedersen SB, Bruun JM, Rasmussen M, Richelsen B (2006) Adiponectin receptors in human adipose tissue: effects of obesity, weight loss, and fat depots. Obesity (Silver Spring) 14:28–35CrossRef

57.

Dietze-Schroeder D, Sell H, Uhlig M, Koenen M, Eckel J (2005) Autocrine action of adiponectin on human fat cells prevents the release of insulin resistance-inducing factors. Diabetes 54:2003–2011PubMedCrossRef

58.

Ge Q, Ryken L, Noel L, Maury E, Brichard SM (2011) Adipokines identified as new downstream targets for adiponectin: lessons from adiponectin-overexpressing or -deficient mice. Am J Physiol Endocrinol Metab 301:E326–E335PubMedCrossRef

59.

Ajuwon KM, Spurlock ME (2005) Adiponectin inhibits LPS-induced NF-κB activation and IL-6 production and increases PPARγ2 expression in adipocytes. Am J Physiol Regul Integr Comp Physiol 288:R1220–R1225PubMedCrossRef

60.

Ohashi K, Parker JL, Ouchi N et al (2010) Adiponectin promotes macrophage polarization toward an anti-inflammatory phenotype. J Biol Chem 285:6153–6160PubMedCrossRef

61.

Yokota T, Oritani K, Takahashi I et al (2000) Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 96:1723–1732PubMed

62.

Wulster-Radcliffe MC, Ajuwon KM, Wang J, Christian JA, Spurlock ME (2004) Adiponectin differentially regulates cytokines in porcine macrophages. Biochem Biophys Res Commun 316:924–929PubMedCrossRef

63.

Wolf AM, Wolf D, Rumpold H, Enrich B, Tilg H (2004) Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes. Biochem Biophys Res Commun 323:630–635PubMedCrossRef

64.

Kumada M, Kihara S, Ouchi N et al (2004) Adiponectin specifically increased tissue inhibitor of metalloproteinase-1 through interleukin-10 expression in human macrophages. Circulation 109:2046–2049PubMedCrossRef

65.

Mandal P, Pratt BT, Barnes M, McMullen MR, Nagy LE (2011) Molecular mechanism for adiponectin-dependent M2 macrophage polarization: link between the metabolic and innate immune activity of full-length adiponectin. J Biol Chem 286:13460–13469PubMedCrossRef

66.

Tian L, Luo N, Klein RL, Chung BH, Garvey WT, Fu Y (2009) Adiponectin reduces lipid accumulation in macrophage foam cells. Atherosclerosis 202:152–161PubMedCrossRef

67.

Ouchi N, Kihara S, Arita Y et al (2001) Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 103:1057–1063PubMedCrossRef

68.

Luo N, Liu J, Chung BH et al (2010) Macrophage adiponectin expression improves insulin sensitivity and protects against inflammation and atherosclerosis. Diabetes 59:791–799PubMedCrossRef

69.

Kusminski CM, McTernan PG, Schraw T et al (2007) Adiponectin complexes in human cerebrospinal fluid: distinct complex distribution from serum. Diabetologia 50:634–642PubMedCrossRef

70.

Qi Y, Takahashi N, Hileman SM et al (2004) Adiponectin acts in the brain to decrease body weight. Nat Med 10:524–529PubMedCrossRef

71.

Park S, Kim DS, Kwon DY, Yang HJ (2011) Long-term central infusion of adiponectin improves energy and glucose homeostasis by decreasing fat storage and suppressing hepatic gluconeogenesis without changing food intake. J Neuroendocrinol 23:687–698PubMedCrossRef

Titel: Adiponectin: mechanistic insights and clinical implications
verfasst von: A. T. Turer
P. E. Scherer
Publikationsdatum: 01.09.2012
Verlag: Springer-Verlag
Erschienen in: Diabetologia / Ausgabe 9/2012
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-012-2598-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Frühzeitige HbA1c-Kontrolle macht sich lebenslang bemerkbar

22.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes von Anfang an intensiv BZ-senkend zu behandeln, wirkt sich positiv auf Komplikationen und Mortalität aus – und das offenbar lebenslang, wie eine weitere Nachfolgeuntersuchung der UKPD-Studie nahelegt.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2012

Similar patterns of myocardial metabolism and perfusion in patients with type 2 diabetes and heart disease of ischaemic and non-ischaemic origin

Age at menarche and risk of type 2 diabetes among African-American and white women in the Atherosclerosis Risk in Communities (ARIC) study

Multimodal imaging of pancreatic beta cells in vivo by targeting transmembrane protein 27 (TMEM27)

A tale of two glucose transporters: how GLUT2 re-emerged as a contender for glucose transport into the human beta cell

Use of class I and class II HLA loci for predicting age at onset of type 1 diabetes in multiple populations